Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Gabriel Steg

Showing results (11-20 of 561) with videos related to

Pageof 57
Sort By:
Circulation|August 24, 2016
Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?Philippe Gabriel Steg, Ronan Roussel
Circulation. Cardiovascular Interventions|June 7, 2018
Emergency Coronary Angiography After Out-of-Hospital Cardiac Arrest: Is It Essential or Futile?Philippe Gabriel Steg, Batric Popovic
Current Atherosclerosis Reports|March 31, 2021
Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard TreatmentFabien Picard, Philippe Gabriel Steg
Current Atherosclerosis Reports|October 9, 2024
PCSK9 Monoclonal Antibodies Have Come a Long WaySandra Zendjebil, Philippe Gabriel Steg
European Journal of Preventive Cardiology|June 19, 2026
The Legacy of Early PCSK9 Inhibitors: Less Lipid, Less MetalJules Mesnier, Philippe Gabriel Steg
Circulation|March 28, 2022
Atrial Fibrillation Screening: The Tools Are Ready, But Should We Do It?Fabrice Extramiana, Philippe Gabriel Steg
European Heart Journal|June 5, 2008
Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke preventionPierre Amarenco, Philippe Gabriel Steg
JAMA|April 2, 2008
Does PERISCOPE provide a new perspective on diabetic treatment?Philippe Gabriel Steg, Michel Marre
Circulation|November 16, 2022
Do We Need Ischemia Testing to Monitor Asymptomatic Patients With Chronic Coronary Syndromes?Philippe Gabriel Steg, John Kikoïne
European Cardiology|March 18, 2020
Direct-acting Anticoagulants in Chronic Coronary SyndromesEmmanuel Sorbets, Philippe Gabriel Steg
Pageof 57

Showing results (11-20 of 561) with videos related to

Sort By:
Pageof 57
Circulation|August 24, 2016
Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?Philippe Gabriel Steg, Ronan Roussel
Circulation. Cardiovascular Interventions|June 7, 2018
Emergency Coronary Angiography After Out-of-Hospital Cardiac Arrest: Is It Essential or Futile?Philippe Gabriel Steg, Batric Popovic
Current Atherosclerosis Reports|March 31, 2021
Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard TreatmentFabien Picard, Philippe Gabriel Steg
Current Atherosclerosis Reports|October 9, 2024
PCSK9 Monoclonal Antibodies Have Come a Long WaySandra Zendjebil, Philippe Gabriel Steg
European Journal of Preventive Cardiology|June 19, 2026
The Legacy of Early PCSK9 Inhibitors: Less Lipid, Less MetalJules Mesnier, Philippe Gabriel Steg
Circulation|March 28, 2022
Atrial Fibrillation Screening: The Tools Are Ready, But Should We Do It?Fabrice Extramiana, Philippe Gabriel Steg
European Heart Journal|June 5, 2008
Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke preventionPierre Amarenco, Philippe Gabriel Steg
JAMA|April 2, 2008
Does PERISCOPE provide a new perspective on diabetic treatment?Philippe Gabriel Steg, Michel Marre
Circulation|November 16, 2022
Do We Need Ischemia Testing to Monitor Asymptomatic Patients With Chronic Coronary Syndromes?Philippe Gabriel Steg, John Kikoïne
European Cardiology|March 18, 2020
Direct-acting Anticoagulants in Chronic Coronary SyndromesEmmanuel Sorbets, Philippe Gabriel Steg
Pageof 57